Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy
Advanced Science · 2026-02 · 13 (9)
DOI: 10.1002/advs.202508433 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Advanced Science, online erschienen am 01.12.2025. Verfasst von Yao Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province,…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antibodies, Monoclonal, Humanized, Adenocarcinoma, Esophagogastric Junction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Hubei Province, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial. Patients with LAGC received neoadjuvant tislelizumab plus SOX before surgery. Biopsies are obtained before treatment, and tumor samples post‐treatment underwent single‐cell RNA sequencing (scRNA‐seq). Spatial transcriptomics is conducted for validation. Cox regression models and Kaplan–Meier analysis are applied. A total of 49 patients are enrolled, and the median progression‐free (PFS) and overall survival (OS) are not achieved. The 3‐year PFS and OS rates are 64.1% and 73.2%, respectively. scRNA‐seq of 22, 248 cells from tumors from seven patients with LAGC enabled annotation of three cancer‐associated fibroblast (CAF) phenotypes. Spatial transcriptomics of gastric cancer samples validate the classification, showing inflammatory CAFs (iCAFs) negatively correlated with immunotherapy efficacy. Patients with LAGC show a favorable prognosis after neoadjuvant tislelizumab plus SOX treatment. CAF heterogeneity is crucial for patients with gastric cancer undergoing immunotherapy, and iCAFs is associated with an immunosuppressive microenvironment during PD‐1 blockade with SOX therapy and validated by in vitro experiments. Patients with LAGC with higher iCAF scores are resistant to SOX PD‐1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430022, China.
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430022, China.
- Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200025, China.
- Institute of Translational Medicine, National Facility for Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China.
ORCID-Profile: Yao Lin, Yuping Yin
Förderung
- Key Research and Development Program of Hubei Province
- National Natural Science Foundation of China
Zitieren
APA
Lin, Y., Sun, X., Li, C., Yang, M., Wu, K., Liu, K., Li, A., Shuai, X., Cai, K., Wang, Z., Wang, G., Zhang, P., Shen, J., Tao, K., & Yin, Y. (2026). Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy. Advanced Science, 13(9). https://doi.org/10.1002/advs.202508433
Vancouver
Lin Y, Sun X, Li C, Yang M, Wu K, Liu K, et al. Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy. Advanced Science. 2026;13(9). doi:10.1002/advs.202508433
BibTeX
@article{Lin2026,
author = {Lin, Yao and Sun, Xiong and Li, Chengguo and Yang, Ming and Wu, Ke and Liu, Ke and Li, Anshu and Shuai, Xiaoming and Cai, Kailin and Wang, Zheng and Wang, Guobin and Zhang, Peng and Shen, Jianfeng and Tao, Kaixiong and Yin, Yuping},
title = {Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {9},
doi = {10.1002/advs.202508433}
}
EUVIMED